A Phase 3 interventional study of zoledronic acid and denosumab in Bone Metastases, sponsored by Amgen. Completed. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-29.
Sponsored by Amgen · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer
725 studies on the registry are indexed under Fractures, Bone; 116 are open to participants now.
This study's enrollment of 1,904 is above the median of 80 across 458 interventional studies indexed under Fractures, Bone.
Browse Fractures, Bone studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: zoledronic acid
Biological: denosumab
Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
Also known as: Zometa
Q4W 120 mg denosumab SC and 4 mg zoledronic acid placebo IV over a minimum of 15 minutes
Time to the First On-Study SRE (Non-inferiority)
Time to the first on-study skeletal-related event (SRE) analyzed for non-inferiority. Kaplan-Meier estimates of the median and its dispersion are reported.
Time frame: Up to 40.5 months
Time to the First On-Study SRE (Superiority)
Time to the first on-study skeletal-related event (SRE), analyzed for superiority of denosumab. Kaplan-Meier estimates of the median and its dispersion are reported.
Time frame: Up to 40.5 months
Time to the First-And-Subsequent On-Study SRE
Time to the first-and-subsequent on-study skeletal-related event (SRE), analyzed for superiority of denosumab using multiple event analysis, the event must occur at least 21 days after the previous SRE. This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events.
Time frame: Up to 40.5 months
Participants were enrolled from 12 May 2006 through 18 December 2008.
| Milestone | Zoledronic Acid | Denosumab |
|---|---|---|
| Started | 951 | 950 |
| Received investigational product | 946 | 942 |
| Completed | 208 | 228 |
| Not completed | 743 | 722 |
| Withdrew: Death | 269 | 294 |
| Withdrew: Withdrawal by subject | 164 | 147 |
| Withdrew: Disease progression | 113 | 117 |
| Withdrew: Adverse event | 43 | 56 |
| Withdrew: Lost to follow-up | 13 | 9 |
| Withdrew: Physician decision | 4 | 1 |
| Withdrew: Noncompliance | 14 | 7 |
| Withdrew: Protocol deviation | 4 | 3 |
| Withdrew: Ineligibility determined | 2 | 3 |
| Withdrew: Participant request | 75 | 52 |
| Withdrew: Other | 42 | 33 |
Time to the first on-study skeletal-related event (SRE) analyzed for non-inferiority. Kaplan-Meier estimates of the median and its dispersion are reported.
| Days | Zoledronic Acid | Denosumab |
|---|---|---|
| Time to the First On-Study SRE (Non-inferiority) | 521.0 (456.00 to 592.00) | 629.0 (573.00 to 757.00) |
Time to the first on-study skeletal-related event (SRE), analyzed for superiority of denosumab. Kaplan-Meier estimates of the median and its dispersion are reported.
| Days | Zoledronic Acid | Denosumab |
|---|---|---|
| Time to the First On-Study SRE (Superiority) | 521.0 (456.0 to 592.0) | 629.0 (573.00 to 757.00) |
Time to the first-and-subsequent on-study skeletal-related event (SRE), analyzed for superiority of denosumab using multiple event analysis, the event must occur at least 21 days after the previous SRE. This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events.
| Events | Zoledronic Acid | Denosumab |
|---|---|---|
| Time to the First-And-Subsequent On-Study SRE | 584 | 494 |
Collected over up to 3 years 5 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zoledronic Acid 4 mg Q4W | — | 568/945 (60.1%) | 853/945 (90.3%) |
| Denosumab 120 mg Q4W | — | 594/943 (63%) | 844/943 (89.5%) |
| Event | Zoledronic Acid 4 mg Q4W | Denosumab 120 mg Q4W |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 82/945 | 108/943 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 56/945 | 34/943 |
| PneumoniaInfections and infestations | 24/945 | 40/943 |
| AstheniaGeneral disorders | 29/945 | 37/943 |
| HaematuriaRenal and urinary disorders | 37/945 | 23/943 |
| DehydrationMetabolism and nutrition disorders | 19/945 | 36/943 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 28/945 | 36/943 |
| Back painMusculoskeletal and connective tissue disorders | 36/945 | 29/943 |
| Urinary retentionRenal and urinary disorders | 35/945 | 32/943 |
| Bone painMusculoskeletal and connective tissue disorders | 34/945 | 24/943 |
| Event | Zoledronic Acid 4 mg Q4W | Denosumab 120 mg Q4W |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 313/945 | 300/943 |
| Back painMusculoskeletal and connective tissue disorders | 271/945 | 290/943 |
| NauseaGastrointestinal disorders | 242/945 | 271/943 |
| Decreased appetiteMetabolism and nutrition disorders | 263/945 | 264/943 |
| FatigueGeneral disorders | 217/945 | 247/943 |
| ConstipationGastrointestinal disorders | 247/945 | 233/943 |
| Bone painMusculoskeletal and connective tissue disorders | 230/945 | 221/943 |
| AstheniaGeneral disorders | 226/945 | 219/943 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 197/945 | 188/943 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 184/945 | 192/943 |
| Age, Continuous(Years) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Mean | 71.0 ± 8.4 | 70.5 ± 8.7 | 70.8 ± 8.6 |
| Sex: Female, Male(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 951 | 950 | 1901 |
| Race/Ethnicity, Customized(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| White or Caucasian | 810 | 829 | 1639 |
| Black or African American | 35 | 38 | 73 |
| Hispanic or Latino | 57 | 45 | 102 |
| Asian | 26 | 22 | 48 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Other | 22 | 15 | 37 |
| Prostate-Specific Antigen (PSA) Stratification Factor(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| PSA level < 10 ng/mL | 145 | 145 | 290 |
| PSA level ≥ 10 ng/mL | 806 | 805 | 1611 |
| Previous Skeletal-Related Event (SRE) Stratification Factor(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Yes | 231 | 232 | 463 |
| No | 720 | 718 | 1438 |
| Current Prostate Cancer Chemotherapy Stratification Factor(Participants) | Zoledronic Acid | Denosumab | Total |
|---|---|---|---|
| Yes | 132 | 132 | 264 |
| No | 819 | 818 | 1637 |
No study locations are listed for this record.
Ran from Apr 2006 to primary completion in Oct 2009, 42 months.
Results were first posted in Mar 2014, 4 years 5 months after primary completion. A results delay was requested in Jun 2010.
Of 14 phase 3 interventional studies under Fractures, Bone, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 46. This study's 42 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab